Clinical Trial Update: Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for oral SM-88 in metastatic HR+/HER2- breast cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor Positive Breast Carcinoma

Drugs mentioned

• SM-88

Snippet

Sponsor: Georgetown University | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-08-28